Oncorus

OverviewSuggest Edit

Oncorus is a biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. Using its two platforms, the company develops a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors.

TypePublic
Founded2015
HQCambridge, MA, USMap
Websiteoncorus.com
Employee Ratings4.1More
Overall CultureFMore
View Jobs (10)

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2020)51(-3%)
Job Openings10
Share Price (Sept 2021)$10.1
Cybersecurity ratingBMore

Key People/Management at Oncorus

Ted Ashburn

Ted Ashburn

President & CEO, Director
John McCabe

John McCabe

Chief Financial Officer
Mitchell H. Finer

Mitchell H. Finer

Executive Chairman
Christophe Quéva

Christophe Quéva

Chief Scientific Officer and Senior Vice President of Research
Lorena Lerner

Lorena Lerner

Vice President of Molecular Biology
Stephanie Duncanson

Stephanie Duncanson

Senior Director of Corporate Strategy and Business Development
Show more

Oncorus Office Locations

Oncorus has an office in Cambridge
Cambridge, MA, US (HQ)
50 Hampshire St #401
Show all (1)

Oncorus Financials and Metrics

Oncorus Revenue

USD

Net income (FY, 2020)

(48.3m)

EBIT (FY, 2020)

(37.2m)

Market capitalization (9-Sept-2021)

276.2m

Closing stock price (9-Sept-2021)

10.1

Cash (31-Dec-2020)

130.3m

EV

188.5m
Oncorus's current market capitalization is $276.2 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

6.0m7.1m10.0m

R&D expense

12.5m24.0m27.2m

Operating expense total

18.6m31.2m37.2m

EBIT

(18.6m)(31.2m)(37.2m)
Half Year
USDH1, 2019H1, 2020

General and administrative expense

2.5m4.1m

R&D expense

12.0m12.6m

Operating expense total

14.4m16.7m

EBIT

(14.4m)(16.7m)
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

20.1m45.3m130.3m

Prepaid Expenses

3.1m

Current Assets

20.9m45.9m133.4m

PP&E

4.3m4.5m4.2m
Quarterly
USDQ2, 2020

Cash

28.9m

Current Assets

30.6m

PP&E

4.8m

Total Assets

35.8m
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(18.0m)(30.7m)(48.3m)

Depreciation and Amortization

956.0k1.1m1.4m

Accounts Payable

284.0k

Cash From Operating Activities

(17.2m)(27.2m)(36.8m)
Quarterly
USDQ2, 2019Q2, 2020

Net Income

(14.3m)(17.2k)

Depreciation and Amortization

519.0k628.0k

Cash From Operating Activities

(11.0m)(15.6m)

Purchases of PP&E

(118.0k)(747.0k)
show all
USDFY, 2018

Financial Leverage

-0.6 x
Show all financial metrics

Oncorus Operating Metrics

Q2, 2020

Research Stage Products

3

Phase I Trials Products

1

Patents (US)

15

Patents (Foreign)

11
Show all operating metrics

Oncorus Acquisitions / Subsidiaries

Company NameDateDeal Size
Oncorus Securities Corporation

Oncorus Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

Learn more about our premium products
SecurityScorecard logo

Oncorus Online and Social Media Presence

Oncorus's Trends

Embed Graph

Oncorus Company Culture

  • Overall Culture

    F

    34/100

  • CEO Rating

    F

    30/100

  • Compensation

    F

    10/100

Learn more on Comparably

Oncorus News and Updates

August 04, 2021

Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported second quarter 2021 financial results and highlighted recent achievements and developments.
July 29, 2021

Oncorus Expands its Board with Appointment of Barbara Yanni

-- Former Merck executive brings extensive experience in corporate development, licensing and financial evaluation, and expertise advising clinical stage public biopharmaceutical companies -- CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biophar…
June 17, 2021

Oncorus Appoints Eric Rubin, M.D. to its Board of Directors

-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceu…
June 15, 2021

Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it will host an upcoming investor day featuring its intravenous (IV)-administered Syntheti…
May 27, 2021

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the nomination of its first Synthetic viral RNA (vRNA) immunotherapy clinical candidates, ONCR-0…
May 04, 2021

Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights

-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H’21 -- -- Company plans to nominate first two intravenously (IV) administered synthetic viral RNA (vRNA) immunotherapy candidates…
Show more

 Oncorus Frequently Asked Questions

  • When was Oncorus founded?

    Oncorus was founded in 2015.

  • Who are Oncorus key executives?

    Oncorus's key executives are Ted Ashburn, John McCabe and Mitchell H. Finer.

  • How many employees does Oncorus have?

    Oncorus has 51 employees.

  • Who are Oncorus competitors?

    Competitors of Oncorus include Italfarmaco, Achilles Therapeutics and Loxo Oncology.

  • Where is Oncorus headquarters?

    Oncorus headquarters is located at 50 Hampshire St #401, Cambridge.

  • Where are Oncorus offices?

    Oncorus has an office in Cambridge.

  • How many offices does Oncorus have?

    Oncorus has 1 office.